

Pharmacovigilance Market Report by Service Provider (In-house, Contract Outsourcing), Product Life Cycle (Pre-clinical, Phase I, Phase II, Phase III, Phase IV), Type (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining), Process Flow (Case Data Management, Signal Detection, Risk Management System), Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, and Others), End Use (Pharmaceuticals Companies, Biotechnology Companies, Medical Device Companies, and Others), and Region 2024-2032

https://marketpublishers.com/r/PD79E1F59C3BEN.html

Date: August 2024 Pages: 135 Price: US\$ 3,899.00 (Single User License) ID: PD79E1F59C3BEN

Abstracts

The global pharmacovigilance market size reached US\$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 15.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. The increasing prevalence of adverse drug reactions (ADRs), coupled with the launch of favorable policies by government bodies to generate awareness about the proper usage of medicines and conduct clinical trials, is primarily stimulating the pharmacovigilance market growth.

Global Pharmacovigilance Market Analysis:

Major Market Drivers: The elevating incidences of various lifestyle diseases, including cardiac disorders, hypertension, diabetes, etc., are augmenting the



usage of drugs across the globe. Consequently, there is an elevating need for pharmacovigilance (PV) to detect previously unknown adverse effects, recognize changes in the frequency or severity, assess the risks and benefits of drugs to determine required actions, etc. This, in turn, is providing significant opportunities in the pharmacovigilance market outlook.

Key Market Trends: One of the key pharmacovigilance market trends includes the development of advanced platforms to ensure automated adverse drug reactions (ADR) reporting. Furthermore, key players are also focusing on enhancing manufacturing operations and streamlining R&D activities, owing to the competitive environment. Besides this, the rising number of clinical trials is expected to fuel the pharmacovigilance market in the forecasted period.

Competitive Landscape: Some of the prominent pharmacovigilance market key players are Accenture plc, ArisGlobal LLC, BioClinica Inc. (Cinven Partners LLP), Capgemini, Cognizant, International Business Machines Corporation, ICON plc., IQVIA Inc., ITClinical, Parexel International Corporation, and Wipro Limited, among many others.

Challenges and Opportunities: According to the pharmacovigilance market analysis, some of the challenges, including stringent regulatory requirements by government bodies, the rising complexities in managing and deriving meaningful insights from a vast amount of data, and the increasing need for balancing comprehensive drug safety monitoring with the pressure to control costs, are hindering the growth of the pharmacovigilance industry across the globe. However, fostering strategic collaborations to ensure the safety of drugs and safeguard public health is expected to propel the pharmacovigilance market share in the coming years.

Global Pharmacovigilance Market Trends:

The Development of Continuous Technological Advancements

The increasing integration of novel technologies, such as machine learning (ML), natural language processing (NLP), artificial intelligence (AI), big data analytics, etc., is enhancing the pharmacovigilance processes. In line with this, these technologies are gaining extensive traction, as they help in identifying adverse events, risk assessments, enabling efficient signal detection, etc., which is expected to fuel the market growth over

Pharmacovigilance Market Report by Service Provider (In-house, Contract Outsourcing), Product Life Cycle (Pre-...



the forecasted period. For instance, Sanofi and Deloitte collaborated on ConvergeHEALTH Safety, a next-generation artificial intelligence (AI) software-as-aservice adverse events case intake platform that transformed pharmacovigilance (PV) processes and addressed some of the industry's most pressing operational safety issues. In line with this, ArisGlobal introduced the go-live of the USFDA Adverse Event Reporting System (FAERS II), an electronic safety reporting platform powered by LifeSphere MultiVigilance, which propelled the market growth. Furthermore, Saama Technologies Inc. developed the new Active Safety Analytics for Pharma (ASAP) products. ASAP is one of the first validated pharmacovigilance solutions to leverage the TreeScan methodology and the United States Food and Drug Administration's (FDA) Sentinel Common Data Model for detecting safety signals.

Stringent Regulations Implemented by Government Bodies

Government authorities across the globe are implementing strict rules in clinical trials and generating awareness regarding the proper utilization of medicines, which is stimulating the usage of pharmacovigilance services. For example, according to a study published in Frontiers in Drug Safety and Regulation, the significance of post-marketing medication evaluation is important for characterizing drug safety profiles in real-world settings. Such studies are further increasing the importance of pharmacovigilance, thereby stimulating the market growth. Moreover, Aurobindo Pharma USA reformulated Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, owing to the presence of N-Nitroso-Quinapril and Nitrosamine Drug Substance Related Impurity (NDSRI). Consequently, the inflating need for medical information among regulatory authorities is expected to fuel the market growth over the forecasted period.

The Rising Adoption of Pharmacovigilance Services by Pharmaceutical Companies

Pharmacovigilance services are extensively adopted by key pharmaceutical companies across the globe, owing to benefits, such as better outcomes over shorter periods and increasing internal resource flexibility. For example, according to the Vaccine Adverse Event Reporting System, 10 cases of anaphylaxis were detected after the administration of a reported 4,041,396 first doses of the Moderna COVID-19 vaccine (2.5 cases per million doses). Consequently, the growing need for pharmacovigilance services is also stimulating the market growth. In addition to this, key industry players are also entering into strategic collaborations, which will continue to propel the pharmacovigilance market over the forecasted period. For example, IQVIA entered into a strategic collaboration with NRx Pharmaceuticals to offer medical information and pharmacovigilance services in preparation for potential regulatory actions.



The Growing Number of Advanced Clinical Trial Phases

To enhance the efficacy of clinical trials, major prominent players are developing advanced clinical trials, which are stimulating the global market for pharmacovigilance. For example, Cognizant entered into a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable's software-as-a-service platform for decentralized clinical trials. In line with this, according to the pharmacovigilance market overview, Viedoc and LINK Medical entered into a partnership established by Viedoc. The collaboration was designed to enhance trial efficiency for LINK Medical and its clients. The partnership allowed for the exchange of needs, experience, ideas, etc., and the testing of new features.

Pharmacovigilance Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pharmacovigilance market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on service provider, product life cycle, type, process flow, therapeutic area, and end use.

Breakup by Service Provider:

In-house

Contract Outsourcing

The report has provided a detailed breakup and analysis of the market based on the service provider. This includes in-house and contract outsourcing.

Breakup by Product Life Cycle:

Pre-clinical

Phase I

Phase II

Phase III

Pharmacovigilance Market Report by Service Provider (In-house, Contract Outsourcing), Product Life Cycle (Pre-...



Phase IV

A detailed breakup and analysis of the market based on the product life cycle has also been provided in the report. This includes pre-clinical, Phase I, Phase II, Phase III, and Phase IV.

Breakup by Type:

Spontaneous Reporting

Intensified ADR Reporting

Targeted Spontaneous Reporting

Cohort Event Monitoring

EHR Mining

The report has provided a detailed breakup and analysis of the market based on the type. This includes spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR Mining.

Breakup by Process Flow:

Case Data Management

Case Logging

Case Data Analysis

Medical Reviewing and Reporting

Signal Detection

Adverse Event Logging



Adverse Event Analysis

Adverse Event Review and Reporting

Risk Management System

Risk Evaluation System

Risk Mitigation System

The report has provided a detailed breakup and analysis of the market based on the process flow. This includes case data management (case logging, case data analysis, medical reviewing and reporting), signal detection (adverse event logging, adverse event analysis, and adverse event review and reporting, and risk management system (risk evaluation system and risk mitigation system).

Breakup by Therapeutic Area:

Oncology Neurology Cardiology Respiratory Systems Others

The report has provided a detailed breakup and analysis of the market based on the therapeutic area. This includes oncology, neurology, cardiology, respiratory systems, and others.

Breakup by End Use:

Pharmaceuticals Companies

Biotechnology Companies



Medical Device Companies

Others

The report has provided a detailed breakup and analysis of the market based on the end-use. This includes pharmaceuticals companies, biotechnology companies, medical device companies, and others.

Breakup by Region:

North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia

Others

Europe

Germany

France



United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the pharmacovigilance top companies are listed below:

Accenture plc

ArisGlobal LLC

BioClinica Inc. (Cinven Partners LLP)



Capgemini

Cognizant

International Business Machines Corporation

ICON plc.

IQVIA Inc.

ITClinical

Parexel International Corporation

Wipro Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Pharmacovigilance Market News:

March 2024: The American Society of Pharmacovigilance (ASP), along with several partners, is focused on advancing drug safety via minimizing ADEs, the fourth leading cause of death in the United States.

February 2024: The Indian Pharmacopoeia Commission (IPC) released the Draft Pharmacovigilance Guidance Document for pharmaceutical products for its latest Version 2.0. The Commission also offered suggestions from Marketing Authorization Holders (MAHs) on the draft document.

February 2024: The US Food and Drug Administration (FDA) Office of Surveillance and Epidemiology (OSE) launched the standardization of Risk Evaluation and Mitigation Strategies (REMS) data to facilitate its use.

Key Questions Answered in This Report:



How has the global pharmacovigilance market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global pharmacovigilance market?

What are the key regional markets?

What is the breakup of the market based on the service provider?

What is the breakup of the market based on the product life cycle?

What is the breakup of the market based on the type?

What is the breakup of the market based on the process flow?

What is the breakup of the market based on the therapeutic area?

What is the breakup of the market based on the end use?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global pharmacovigilance market and who are the key players?

What is the degree of competition in the industry?



Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL PHARMACOVIGILANCE MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY SERVICE PROVIDER

- 6.1 In-house
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Contract Outsourcing
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast



7 MARKET BREAKUP BY PRODUCT LIFE CYCLE

7.1 Pre-clinical
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Phase I
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Phase II
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Phase III
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Phase IV
7.5.1 Market Trends
7.5.2 Market Forecast

8 MARKET BREAKUP BY TYPE

8.1 Spontaneous Reporting
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Intensified ADR Reporting
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Targeted Spontaneous Reporting
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Cohort Event Monitoring
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 EHR Mining
8.5.1 Market Forecast

9 MARKET BREAKUP BY PROCESS FLOW

9.1 Case Data Management



- 9.1.1 Market Trends
- 9.1.2 Major Types
 - 9.1.2.1 Case Logging
 - 9.1.2.2 Case Data Analysis
 - 9.1.2.3 Medical Reviewing and Reporting
- 9.1.3 Market Forecast
- 9.2 Signal Detection
 - 9.2.1 Market Trends
 - 9.2.2 Major Types
 - 9.2.2.1 Adverse Event Logging
 - 9.2.2.2 Adverse Event Analysis
 - 9.2.2.3 Adverse Event Review and Reporting
- 9.2.3 Market Forecast
- 9.3 Risk Management System
- 9.3.1 Market Trends
- 9.3.2 Major Types
 - 9.3.2.1 Risk Evaluation System
- 9.3.2.2 Risk Mitigation System
- 9.3.3 Market Forecast

10 MARKET BREAKUP BY THERAPEUTIC AREA

- 10.1 Oncology
 - 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Neurology
 - 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Cardiology
 - 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 10.4 Respiratory Systems
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
- 10.5 Others
 - 10.5.1 Market Trends
 - 10.5.2 Market Forecast

11 MARKET BREAKUP BY END USE



- 11.1 Pharmaceuticals Companies
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
- 11.2 Biotechnology Companies
 - 11.2.1 Market Trends
 - 11.2.2 Market Forecast
- 11.3 Medical Device Companies
 - 11.3.1 Market Trends
 - 11.3.2 Market Forecast
- 11.4 Others
- 11.4.1 Market Trends
- 11.4.2 Market Forecast

12 MARKET BREAKUP BY REGION

12.1 North America 12.1.1 United States 12.1.1.1 Market Trends 12.1.1.2 Market Forecast 12.1.2 Canada 12.1.2.1 Market Trends 12.1.2.2 Market Forecast 12.2 Asia-Pacific 12.2.1 China 12.2.1.1 Market Trends 12.2.1.2 Market Forecast 12.2.2 Japan 12.2.2.1 Market Trends 12.2.2.2 Market Forecast 12.2.3 India 12.2.3.1 Market Trends 12.2.3.2 Market Forecast 12.2.4 South Korea 12.2.4.1 Market Trends 12.2.4.2 Market Forecast 12.2.5 Australia 12.2.5.1 Market Trends 12.2.5.2 Market Forecast



12.2.6 Indonesia 12.2.6.1 Market Trends 12.2.6.2 Market Forecast 12.2.7 Others 12.2.7.1 Market Trends 12.2.7.2 Market Forecast 12.3 Europe 12.3.1 Germany 12.3.1.1 Market Trends 12.3.1.2 Market Forecast 12.3.2 France 12.3.2.1 Market Trends 12.3.2.2 Market Forecast 12.3.3 United Kingdom 12.3.3.1 Market Trends 12.3.3.2 Market Forecast 12.3.4 Italy 12.3.4.1 Market Trends 12.3.4.2 Market Forecast 12.3.5 Spain 12.3.5.1 Market Trends 12.3.5.2 Market Forecast 12.3.6 Russia 12.3.6.1 Market Trends 12.3.6.2 Market Forecast 12.3.7 Others 12.3.7.1 Market Trends 12.3.7.2 Market Forecast 12.4 Latin America 12.4.1 Brazil 12.4.1.1 Market Trends 12.4.1.2 Market Forecast 12.4.2 Mexico 12.4.2.1 Market Trends 12.4.2.2 Market Forecast 12.4.3 Others 12.4.3.1 Market Trends 12.4.3.2 Market Forecast 12.5 Middle East and Africa



- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast

13 SWOT ANALYSIS

- 13.1 Overview
- 13.2 Strengths
- 13.3 Weaknesses
- 13.4 Opportunities
- 13.5 Threats

14 VALUE CHAIN ANALYSIS

15 PORTERS FIVE FORCES ANALYSIS

- 15.1 Overview
- 15.2 Bargaining Power of Buyers
- 15.3 Bargaining Power of Suppliers
- 15.4 Degree of Competition
- 15.5 Threat of New Entrants
- 15.6 Threat of Substitutes

16 PRICE ANALYSIS

17 COMPETITIVE LANDSCAPE

17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
17.3.1 Accenture plc
17.3.1.1 Company Overview
17.3.1.2 Product Portfolio
17.3.1.3 Financials
17.3.1.4 SWOT Analysis
17.3.2 ArisGlobal LLC
17.3.2.1 Company Overview
17.3.2.2 Product Portfolio
17.3.3 BioClinica Inc. (Cinven Partners LLP)



- 17.3.3.1 Company Overview
- 17.3.3.2 Product Portfolio
- 17.3.3.3 SWOT Analysis
- 17.3.4 Capgemini
 - 17.3.4.1 Company Overview
- 17.3.4.2 Product Portfolio
- 17.3.5 Cognizant
 - 17.3.5.1 Company Overview
- 17.3.5.2 Product Portfolio
- 17.3.5.3 Financials
- 17.3.5.4 SWOT Analysis
- 17.3.6 International Business Machines Corporation
- 17.3.6.1 Company Overview
- 17.3.6.2 Product Portfolio
- 17.3.6.3 Financials
- 17.3.6.4 SWOT Analysis
- 17.3.7 ICON plc.
- 17.3.7.1 Company Overview
- 17.3.7.2 Product Portfolio
- 17.3.7.3 Financials
- 17.3.7.4 SWOT Analysis
- 17.3.8 IQVIA Inc.
 - 17.3.8.1 Company Overview
- 17.3.8.2 Product Portfolio
- 17.3.8.3 Financials
- 17.3.8.4 SWOT Analysis
- 17.3.9 ITClinical
- 17.3.9.1 Company Overview
- 17.3.9.2 Product Portfolio
- 17.3.10 Parexel International Corporation
- 17.3.10.1 Company Overview
- 17.3.10.2 Product Portfolio
- 17.3.10.3 SWOT Analysis
- 17.3.11 Wipro Limited
- 17.3.11.1 Company Overview
- 17.3.11.2 Product Portfolio
- 17.3.11.3 Financials
- 17.3.11.4 SWOT Analysis



List Of Tables

LIST OF TABLES

Table 1: Global: Pharmacovigilance Market: Key Industry Highlights, 2023 and 2032 Table 2: Global: Pharmacovigilance Market Forecast: Breakup by Service Provider (in Million US\$), 2024-2032

Table 3: Global: Pharmacovigilance Market Forecast: Breakup by Product Life Cycle (in Million US\$), 2024-2032

Table 4: Global: Pharmacovigilance Market Forecast: Breakup by Type (in Million US\$), 2024-2032

Table 5: Global: Pharmacovigilance Market Forecast: Breakup by Process Flow (in Million US\$), 2024-2032

Table 6: Global: Pharmacovigilance Market Forecast: Breakup by Therapeutic Area (in Million US\$), 2024-2032

Table 7: Global: Pharmacovigilance Market Forecast: Breakup by End Use (in Million US\$), 2024-2032

Table 8: Global: Pharmacovigilance Market Forecast: Breakup by Region (in Million US\$), 2024-2032

 Table 9: Global: Pharmacovigilance Market: Competitive Structure

Table 10: Global: Pharmacovigilance Market: Key Players



List Of Figures

LIST OF FIGURES

Figure 1: Global: Pharmacovigilance Market: Major Drivers and Challenges Figure 2: Global: Pharmacovigilance Market: Sales Value (in Billion US\$), 2018-2023 Figure 3: Global: Pharmacovigilance Market Forecast: Sales Value (in Billion US\$), 2024-2032 Figure 4: Global: Pharmacovigilance Market: Breakup by Service Provider (in %), 2023 Figure 5: Global: Pharmacovigilance Market: Breakup by Product Life Cycle (in %), 2023 Figure 6: Global: Pharmacovigilance Market: Breakup by Type (in %), 2023 Figure 7: Global: Pharmacovigilance Market: Breakup by Process Flow (in %), 2023 Figure 8: Global: Pharmacovigilance Market: Breakup by Therapeutic Area (in %), 2023 Figure 9: Global: Pharmacovigilance Market: Breakup by End Use (in %), 2023 Figure 10: Global: Pharmacovigilance Market: Breakup by Region (in %), 2023 Figure 11: Global: Pharmacovigilance (In-house) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 12: Global: Pharmacovigilance (In-house) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 13: Global: Pharmacovigilance (Contract Outsourcing) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 14: Global: Pharmacovigilance (Contract Outsourcing) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 15: Global: Pharmacovigilance (Pre-clinical) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 16: Global: Pharmacovigilance (Pre-clinical) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 17: Global: Pharmacovigilance (Phase I) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 18: Global: Pharmacovigilance (Phase I) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 19: Global: Pharmacovigilance (Phase II) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 20: Global: Pharmacovigilance (Phase II) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 21: Global: Pharmacovigilance (Phase III) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 22: Global: Pharmacovigilance (Phase III) Market Forecast: Sales Value (in



Million US\$), 2024-2032 Figure 23: Global: Pharmacovigilance (Phase IV) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 24: Global: Pharmacovigilance (Phase IV) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 25: Global: Pharmacovigilance (Spontaneous Reporting) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 26: Global: Pharmacovigilance (Spontaneous Reporting) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 27: Global: Pharmacovigilance (Intensified ADR Reporting) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 28: Global: Pharmacovigilance (Intensified ADR Reporting) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 29: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 30: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 31: Global: Pharmacovigilance (Cohort Event Monitoring) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 32: Global: Pharmacovigilance (Cohort Event Monitoring) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 33: Global: Pharmacovigilance (EHR Mining) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 34: Global: Pharmacovigilance (EHR Mining) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 35: Global: Pharmacovigilance (Case Data Management) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 36: Global: Pharmacovigilance (Case Data Management) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 37: Global: Pharmacovigilance (Signal Detection) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 38: Global: Pharmacovigilance (Signal Detection) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 39: Global: Pharmacovigilance (Risk Management System) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 40: Global: Pharmacovigilance (Risk Management System) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 41: Global: Pharmacovigilance (Oncology) Market: Sales Value (in Million US\$), 2018 & 2023



Figure 42: Global: Pharmacovigilance (Oncology) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 43: Global: Pharmacovigilance (Neurology) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 44: Global: Pharmacovigilance (Neurology) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 45: Global: Pharmacovigilance (Cardiology) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 46: Global: Pharmacovigilance (Cardiology) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 47: Global: Pharmacovigilance (Respiratory Systems) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 48: Global: Pharmacovigilance (Respiratory Systems) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 49: Global: Pharmacovigilance (Other Therapeutic Areas) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 50: Global: Pharmacovigilance (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 51: Global: Pharmacovigilance (Pharmaceuticals Companies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 52: Global: Pharmacovigilance (Pharmaceuticals Companies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 53: Global: Pharmacovigilance (Biotechnology Companies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 54: Global: Pharmacovigilance (Biotechnology Companies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 55: Global: Pharmacovigilance (Medical Device Companies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 56: Global: Pharmacovigilance (Medical Device Companies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 57: Global: Pharmacovigilance (Other End Uses) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 58: Global: Pharmacovigilance (Other End Uses) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 59: North America: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 60: North America: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 61: United States: Pharmacovigilance Market: Sales Value (in Million US\$), 2018



& 2023

Figure 62: United States: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 63: Canada: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 64: Canada: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 65: Asia-Pacific: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 66: Asia-Pacific: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 67: China: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023 Figure 68: China: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 69: Japan: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 70: Japan: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 71: India: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023 Figure 72: India: Pharmacovigilance Market Forecast: Sales Value (in Million US\$),

2024-2032

Figure 73: South Korea: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 74: South Korea: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 75: Australia: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 76: Australia: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 77: Indonesia: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 78: Indonesia: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 79: Others: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 80: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 81: Europe: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023



Figure 82: Europe: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 83: Germany: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 84: Germany: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 85: France: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 86: France: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 87: United Kingdom: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 88: United Kingdom: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 89: Italy: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023 Figure 90: Italy: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 91: Spain: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023 Figure 92: Spain: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 93: Russia: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 94: Russia: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 95: Others: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 96: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 97: Latin America: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 98: Latin America: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 99: Brazil: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023 Figure 100: Brazil: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 101: Mexico: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 102: Mexico: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032



Figure 103: Others: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 104: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 105: Middle East and Africa: Pharmacovigilance Market: Sales Value (in Million US\$), 2018 & 2023

Figure 106: Middle East and Africa: Pharmacovigilance Market: Breakup by Country (in %), 2023

Figure 107: Middle East and Africa: Pharmacovigilance Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 108: Global: Pharmacovigilance Industry: SWOT Analysis

Figure 109: Global: Pharmacovigilance Industry: Value Chain Analysis

Figure 110: Global: Pharmacovigilance Industry: Porter's Five Forces Analysis



I would like to order

Product name: Pharmacovigilance Market Report by Service Provider (In-house, Contract Outsourcing), Product Life Cycle (Pre-clinical, Phase I, Phase II, Phase III, Phase IV), Type (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining), Process Flow (Case Data Management, Signal Detection, Risk Management System), Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, and Others), End Use (Pharmaceuticals Companies, Biotechnology Companies, Medical Device Companies, and Others), and Region 2024-2032

Product link: https://marketpublishers.com/r/PD79E1F59C3BEN.html

Price: US\$ 3,899.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/PD79E1F59C3BEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _



Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970